1. Home
  2. MYGN vs KYN Comparison

MYGN vs KYN Comparison

Compare MYGN & KYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

N/A

Current Price

$4.16

Market Cap

372.1M

Sector

Health Care

ML Signal

N/A

Logo Kayne Anderson Energy Infrastructure Fund Inc.

KYN

Kayne Anderson Energy Infrastructure Fund Inc.

N/A

Current Price

$13.73

Market Cap

2.4B

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
MYGN
KYN
Founded
1991
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
372.1M
2.4B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
MYGN
KYN
Price
$4.16
$13.73
Analyst Decision
Hold
Analyst Count
9
0
Target Price
★ $3.41
N/A
AVG Volume (30 Days)
★ 1.9M
291.0K
Earning Date
11-02-2026
01-01-0001
Dividend Yield
N/A
★ 8.99%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $771,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$5.57
N/A
P/E Ratio
★ N/A
$20.75
Revenue Growth
★ 2.33
N/A
52 Week Low
$2.74
$11.31
52 Week High
$8.59
$15.17

Technical Indicators

Market Signals
Indicator
MYGN
KYN
Relative Strength Index (RSI) 65.93 19.93
Support Level $4.24 $13.17
Resistance Level $4.79 $14.35
Average True Range (ATR) 0.25 0.22
MACD 0.07 -0.11
Stochastic Oscillator 90.16 0.67

Price Performance

Historical Comparison
MYGN
KYN

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

About KYN Kayne Anderson Energy Infrastructure Fund Inc.

Kayne Anderson Energy Infrastructure Fund, Inc is a non-diversified, closed-end fund. Its investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to the stockholder. The Company invests in various sectors, which include midstream energy companies, renewable infrastructure companies, and utility companies. The company seeks to achieve its objectives by investing a majority of its total assets in the securities of Energy Infrastructure companies.

Share on Social Networks: